ISRCTN34634478已完成不适用
Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclophosphamide in the treatment of proliferative lupus nephritis
Sponsor not yet defined (The Netherlands)0 个研究点目标入组 124 人开始时间: 2006年1月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 - 70 years
- •2. Systemic lupus erythematosus (SLE) (presence of at least 4 American College of Rheumatology [ACR]-criteria for SLE)
- •3. Proliferative lupus nephritis:
- •3.1. Biopsy proven lupus nephritis World Health Organization (WHO) class III or IV (according to Churg 1995)
- •3.2. 'Active sediment': greater than 5 erythrocytes per high powered field (HPF) and/or cel cylinders
- •3.3. Proteinuria greater than 0.5 g/day
- •4. Adequate contraception
- •5. Informed consent
排除标准
- •1. Active infection
- •2. Pregnancy
- •3. Known allergy for one of the study drugs
- •4. Malignancy less than 5 years prior to inclusion
研究者
相似试验
尚未招募
不适用
Randomized controlled trial for reduced cumulative immuno-suppression in the treatment of primary membranous nephropathy.CTRI/2020/04/024880Dr Manu Dogra
招募中
4 期
Decreased immunosuppression in Primary Membranous NephropathyCTRI/2019/09/021287Postgraduate Institute of Medical Education and Research
招募中
不适用
Comparative Study of Oral Cyclophosphamide and Mycophenolate mofetil in Childhood Nephrotic SyndromeCTRI/2021/06/034421GURDEEP SINGH DHOORIA
进行中（未招募）
1 期
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
进行中（未招募）
不适用
_advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma.EUCTR2014-000196-85-FRInstitut Bergonié